Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $8.50

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Buy” from the four brokerages that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $9.00.

Several equities research analysts recently commented on the stock. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. The Goldman Sachs Group lifted their price objective on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 6th. Finally, Truist Financial boosted their price objective on Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 12th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AMRX. Vanguard Group Inc. boosted its stake in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock worth $83,193,000 after buying an additional 85,846 shares during the last quarter. Sanders Morris Harris LLC purchased a new position in Amneal Pharmaceuticals in the 1st quarter valued at approximately $1,513,000. Hillsdale Investment Management Inc. raised its holdings in Amneal Pharmaceuticals by 19.7% in the first quarter. Hillsdale Investment Management Inc. now owns 699,719 shares of the company’s stock valued at $4,240,000 after acquiring an additional 115,100 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Amneal Pharmaceuticals by 417.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock valued at $218,000 after purchasing an additional 29,133 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Amneal Pharmaceuticals during the first quarter worth approximately $1,109,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Up 1.6 %

Amneal Pharmaceuticals stock opened at $8.04 on Monday. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.65 and a quick ratio of 0.97. The stock has a market capitalization of $2.48 billion, a PE ratio of -14.36 and a beta of 1.23. The business has a 50 day simple moving average of $7.08 and a 200-day simple moving average of $6.38. Amneal Pharmaceuticals has a 12 month low of $3.36 and a 12 month high of $8.15.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.